20/20 Biolabs, Inc. (AIDX): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$1.92M

Year ended 2025-12-31

-$2.79M

Trailing 12 months to 2026-06-30

2024-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$1.92M	n/m	2026-03-31, From 2025-01-01
2024-12-31	-$2.60M	n/a	2026-03-31, From 2024-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
20/20 Biolabs, Inc. (AIDX)	2025-12-31	-$1.92M	n/m
NeoGenomics Inc (NEO)	2025-12-31	$5.23M	-25.5%
UL Solutions Inc. (ULS)	2025-12-31	$600.00M	+14.5%
Hypha Labs, Inc. (FUNI)	2025-09-30	-$380.0K	n/m

Compare AIDX, NEO, ULS, FUNI side by side · Screen every company in Services-Testing Laboratories ↗